Danske Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17 Hold
2
– – ﹤0.01% 1049
2026
Q2
$20 Hold
2
– – ﹤0.01% 1049
2026
Q1
$19 Buy
+2
New +$16 ﹤0.01% 1068
2025
Q3
– Sell
-700
Closed -$6.27K – 1498
2025
Q2
$6.27K Sell
700
-192,864
-100% -$1.8M ﹤0.01% 1323
2025
Q1
$1.45M Buy
+193,564
New +$1.56M ﹤0.01% 761

Other funds holding BCRX

Danske Bank's BCRX Position: Q3 2026 in Review

Danske Bank held its BioCryst Pharmaceuticals (BCRX) position steady in Q3 2026 at 2 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Danske Bank first reported a position in BCRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.45M in Q1 2025. 331 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Danske Bank held 2 shares of BioCryst Pharmaceuticals worth $17 as of Q3 2026.
  • Danske Bank left its BioCryst Pharmaceuticals share count unchanged in Q3 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #1049 holding.
  • Danske Bank first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Danske Bank's BioCryst Pharmaceuticals position peaked at $1.45M in Q1 2025.
  • 331 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.